维生素中国E-新闻

Welcome to Vitamins China E-News!

A number of domestic vitamin manufacturers released their finanical reports of Q3 in Nov., which showed that many enterprises were confronted with performance decline, like Zhejiang NHU Co., Ltd. whose revenue of Q3 decreased by 22.8% month on month, and Northeast Pharmaceutical Group Co., Ltd. disclosing loss in the same period. It seems that relying too much on the vitamin business is not benefited for enterprises to make profit. At present, some enterprises, like Xiamen Kingdomway Group Co., Ltd. (Kingdomway) and Zhejiang Medicine Co., Ltd., are shifting their strategic focus away from vitamin business to others gradually, mainly by turning upstream material manufacturing business into downstream production and sales, and by getting away from vitamin business to enlarge other business. Of course, no matter which developing direction enterprises choose, would they face all kinds of challenges. 

At the same time, the market prices of domestic vitamins are rather stable. Due to the weak demand for vitamins, in Nov., the prices of most vitamins were almost identical to those of last month, remaining at low levels. For example, the VC price maintained around USD4,000/t in nearly two months. By contrast, the price of feed grade vitamin B7 had gone up remarkably in Nov., which reached USD19,527/t, with 20% month-on-month growth rate. This was resulted from production halts of some domestic manufacturers.

In addition, many enterprises launched new products since this month, like CSPC launching vitamin drink and Haineng Bioengineering formally launching 25-Hydroxyvitamin D3, which may bring new opportunities for vitamin industry.

To be noticed, the RMB/USD exchange rate in this issue is 6.1525 (the People’s Bank of China). If there are any specific topics you would like us to cover or any subjects you would like us to investigate in more details, please contact us by +86-20-3761 6606, or econtact@cnchemicals.com.